Journal Article
. 2016 Mar;34(20).
doi: 10.1200/JCO.2015.63.5383.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz 1 Ulrike A Nitz 2 Matthias Christgen 2 Ronald E Kates 2 Steven Shak 2 Michael Clemens 2 Stefan Kraemer 2 Bahriye Aktas 2 Sherko Kuemmel 2 Toralf Reimer 2 Manfred Kusche 2 Volker Heyl 2 Fatemeh Lorenz-Salehi 2 Marianne Just 2 Daniel Hofmann 2 Tom Degenhardt 2 Cornelia Liedtke 2 Christer Svedman 2 Rachel Wuerstlein 2 Hans H Kreipe 2 Nadia Harbeck 2 
Affiliations
  • PMID: 26926676
  •     77 citations

Abstract

Purpose: The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool in early hormone receptor-positive breast cancer (BC); however, only a few prospective outcome results have been available so far. In the phase III PlanB trial, RS was prospectively used to define a subset of patients who received only endocrine therapy. We present 3-year outcome data and concordance analysis (among biomarkers/RS).

Patients And Methods: Central tumor bank was established prospectively from PlanB (intermediate and high-risk, locally human epidermal growth factor receptor 2-negative BC). After an early amendment, HR-positive, pN0-1 patients with RS ≤ 11 were recommended to omit chemotherapy.

Results: From 2009 to 2011, PlanB enrolled 3,198 patients with a median age of 56 years; 41.1% had node-positive and 32.5% grade 3 disease. In 348 patients (15.3%), chemotherapy was omitted based on RS ≤ 11. After 35 months median follow-up, 3-year disease-free survival in patients with RS ≤ 11 and endocrine therapy alone was 98% versus 92% and 98% in RS > 25 and RS 12 to 25 in chemotherapy-treated patients, respectively. Nodal status, central and local grade, the Ki-67 protein encoded by the MKI67 gene, estrogen receptor, progesterone receptor, tumor size, and RS were univariate prognostic factors for disease-free survival; only nodal status, both central and local grade, and RS were independent multivariate factors. Histologic grade was discordant between central and local laboratories in 44%. RS was positively but moderately correlated with the Ki-67 protein encoded by the MKI67 gene and grade and negatively correlated with progesterone receptor and estrogen receptor.

Conclusion: In this prospective trial, patients with enhanced clinical risk and omitted chemotherapy on the basis of RS ≤ 11 had excellent 3-year survival. The substantial discordance observed between traditional prognostic markers and RS emphasizes the need for standardized assessment and supports the potential integration of standardized, well-validated genomic assays such as RS with clinicopathologic prognostic factors for chemotherapy indication in early hormone receptor-positive BC.

[Histological grading of breast cancer].
M Christgen, F Länger, H Kreipe.
Pathologe, 2016 Jul 02; 37(4). PMID: 27363708
Review.
Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Carlos H Barcenas, Akshara Raghavendra, +10 authors, Debu Tripathy.
Cancer, 2017 Feb 16; 123(13). PMID: 28199747    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
Review.
Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
Jiayi Wu, Yan Fang, +11 authors, Kunwei Shen.
Oncotarget, 2017 Apr 14; 8(24). PMID: 28404972    Free PMC article.
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D Bear, Wen Wan, +8 authors, Amy P Sing.
J Surg Oncol, 2017 Apr 14; 115(8). PMID: 28407247    Free PMC article.
An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
Zsuzsanna Varga, Annette Lebeau, +18 authors, Giuseppe Viale.
Breast Cancer Res, 2017 May 12; 19(1). PMID: 28490348    Free PMC article.
Quality assurance trials for Ki67 assessment in pathology.
M Raap, S Ließem, +5 authors, H Kreipe.
Virchows Arch, 2017 May 13; 471(4). PMID: 28497316
Tumor Biology and Response to Chemotherapy Impact Breast Cancer-specific Survival in Node-positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: Long-term Follow-up From ACOSOG Z1071 (Alliance).
Judy C Boughey, Karla V Ballman, +5 authors, Kelly K Hunt.
Ann Surg, 2017 Jun 29; 266(4). PMID: 28657941    Free PMC article.
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.
Valentina I Petkov, Dave P Miller, +21 authors, Steven Shak.
NPJ Breast Cancer, 2017 Jul 20; 2. PMID: 28721379    Free PMC article.
Highly Cited.
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Michael Untch, Jens Huober, +18 authors, Cornelia Liedtke.
Geburtshilfe Frauenheilkd, 2017 Aug 05; 77(6). PMID: 28769126    Free PMC article.
How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment.
Giuseppe Curigliano.
Breast Care (Basel), 2017 Aug 09; 12(3). PMID: 28785179    Free PMC article.
Estrogen receptor (ESR1) mutation in bone metastases from breast cancer.
Stephan Bartels, Matthias Christgen, +4 authors, Hans Kreipe.
Mod Pathol, 2017 Aug 12; 31(1). PMID: 28799536
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
G Curigliano, H J Burstein, +52 authors, B Xu.
Ann Oncol, 2017 Aug 26; 28(8). PMID: 28838210    Free PMC article.
Highly Cited.
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +13 authors, Noa Ben-Baruch.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900632    Free PMC article.
Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.
Salomon M Stemmer, Mariana Steiner, +21 authors, Nicky Liebermann.
NPJ Breast Cancer, 2017 Sep 14; 3. PMID: 28900633    Free PMC article.
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.
Prema P Peethambaram, Tanya L Hoskin, +3 authors, Judy C Boughey.
NPJ Breast Cancer, 2017 Oct 27; 3. PMID: 29067357    Free PMC article.
Gene Expression Profiling in Breast Cancer and Its Effect on Therapy Selection in Early-Stage Breast Cancer.
E Nilüfer Güler.
Eur J Breast Health, 2017 Oct 31; 13(4). PMID: 29082373    Free PMC article.
Review.
Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.
Volker Möbus, Susanne Hell, Marcus Schmidt.
Geburtshilfe Frauenheilkd, 2017 Nov 03; 77(10). PMID: 29093601    Free PMC article.
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer.
Maria Vittoria Dieci, Valentina Guarneri, +15 authors, PierFranco Conte.
Oncologist, 2017 Nov 15; 23(3). PMID: 29133514    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint.
Ling Xin, Yin-Hua Liu, Tracey A Martin, Wen G Jiang.
World J Oncol, 2017 Nov 18; 8(2). PMID: 29147432    Free PMC article.
Review.
Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
Oluwadamilola M Fayanju, Ko Un Park, Anthony Lucci.
Ann Surg Oncol, 2017 Nov 22; 25(2). PMID: 29159748    Free PMC article.
Review.
Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Nita Amornsiripanitch, Vicky T Nguyen, +4 authors, Savannah C Partridge.
J Magn Reson Imaging, 2017 Nov 28; 48(1). PMID: 29178616    Free PMC article.
Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.
Steffen Dörfel, Claus-Christoph Steffens, +6 authors, TMK-Group (Tumour Registry Breast Cancer).
Breast Cancer, 2017 Dec 06; 25(3). PMID: 29204847    Free PMC article.
Large-scale DNA organization is a prognostic marker of breast cancer survival.
Martial Guillaud, Qian Ye, +5 authors, Mira Keyes.
Med Oncol, 2017 Dec 08; 35(1). PMID: 29214466
Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia Torres, Maureen Trudeau, +7 authors, Andrea Eisen.
Oncologist, 2018 Jan 27; 23(7). PMID: 29371476    Free PMC article.
Spotlight on the utility of the Oncotype DX® breast cancer assay.
Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann.
Int J Womens Health, 2018 Mar 06; 10. PMID: 29503586    Free PMC article.
Review.
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.
Jonathan Chen, Xian Wu, +2 authors, Himanshu Nagar.
Breast Cancer Res, 2018 Apr 18; 20(1). PMID: 29661221    Free PMC article.
The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).
Frédérique Penault-Llorca, Thomas Filleron, +12 authors, Henri Roché.
BMC Cancer, 2018 May 08; 18(1). PMID: 29728098    Free PMC article.
Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.
M M Gage, W C Mylander, +9 authors, R S Jackson.
Ann Oncol, 2018 May 23; 29(5). PMID: 29788166    Free PMC article.
Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology.
Danielle M Bello, Christy Russell, +2 authors, Monica Morrow.
Ann Surg Oncol, 2018 Jul 04; 25(10). PMID: 29968028    Free PMC article.
Personalizing Radiation Treatment Delivery in the Management of Breast Cancer.
Kamran A Ahmed, G Daniel Grass, +7 authors, Roberto Diaz.
Int J Breast Cancer, 2018 Jul 10; 2018. PMID: 29984003    Free PMC article.
Review.
Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Matthias Christgen, Stephan Bartels, +4 authors, Hans Kreipe.
Virchows Arch, 2018 Aug 11; 473(5). PMID: 30094493
Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Eleftherios P Mamounas, Christy A Russell, +2 authors, Kathy S Albain.
NPJ Breast Cancer, 2018 Aug 30; 4. PMID: 30155517    Free PMC article.
Review.
Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study.
Wei Wang, Xiaosong Chen, +12 authors, Kunwei Shen.
J Cancer, 2018 Oct 03; 9(18). PMID: 30271480    Free PMC article.
Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.
Wenyong Tan, Ming Yang, +2 authors, Weixi Shen.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349367    Free PMC article.
Review.
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Maria Vittoria Dieci, Valentina Guarneri, +16 authors, Veneto Oncology Network.
Oncologist, 2019 Jun 04; 24(11). PMID: 31152079    Free PMC article.
Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer.
Tanja Ovcaricek, Iztok Takac, Erika Matos.
Radiol Oncol, 2019 Sep 26; 53(3). PMID: 31553709    Free PMC article.
Review.
21-Gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes.
Wei Wang, Lin Lin, +11 authors, Kunwei Shen.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579428    Free PMC article.
Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
Seho Park, Yunan Han, +7 authors, Yikyung Park.
Breast Cancer Res, 2019 Oct 18; 21(1). PMID: 31619259    Free PMC article.
Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy.
Salomon M Stemmer, Mariana Steiner, +16 authors, David B Geffen.
NPJ Breast Cancer, 2019 Nov 16; 5. PMID: 31728408    Free PMC article.
Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019).
Diana Lüftner, Ingo Bauerfeind, +21 authors, Marc Thill.
Breast Care (Basel), 2019 Dec 05; 14(5). PMID: 31798392    Free PMC article.
Review.
Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
Marie Alexandre, Aurélie Maran-Gonzalez, +6 authors, Séverine Guiu.
Cancer Manag Res, 2019 Dec 19; 11. PMID: 31849525    Free PMC article.
Review.
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Philip D Poorvu, Shari I Gelber, +12 authors, Ann H Partridge.
J Clin Oncol, 2019 Dec 07; 38(7). PMID: 31809240    Free PMC article.
21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes.
Yiwei Tong, Jiayi Wu, +6 authors, Kunwei Shen.
Sci Rep, 2019 Sep 13; 9(1). PMID: 31511599    Free PMC article.
Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Abiola F Ibraheem, David J Press, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2018 Nov 06; 125(2). PMID: 30387876    Free PMC article.
Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?
Kevin Kalinsky, Ruth M O'Regan.
Cancer, 2018 Nov 06; 125(2). PMID: 30387877    Free PMC article.
Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage.
Jieun Koh, Min Jung Kim.
Korean J Radiol, 2019 Jan 11; 20(1). PMID: 30627023    Free PMC article.
Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
A Matikas, T Foukakis, S Swain, J Bergh.
Ann Oncol, 2019 May 28; 30(7). PMID: 31131397    Free PMC article.
Review.
Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment.
Ontario Health (Quality).
Ont Health Technol Assess Ser, 2020 Apr 15; 20(10). PMID: 32284770    Free PMC article.
Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
Cornelia Kolberg-Liedtke, Oleg Gluz, +13 authors, Nadia Harbeck.
Breast Cancer Res, 2020 May 16; 22(1). PMID: 32408905    Free PMC article.
21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort.
J Bryan Iorgulescu, Rachel A Freedman, +2 authors, Jane E Brock.
JCO Precis Oncol, 2019 Jan 01; 3. PMID: 32457931    Free PMC article.
Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany.
Vincent P Walter, Florin-Andrei Taran, +6 authors, Andreas Daniel Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Jun 23; 80(6). PMID: 32565552    Free PMC article.
Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.
Aurelia Noske, Sophie-Isabelle Anders, +6 authors, Evelyn Klein.
Breast, 2019 Dec 02; 49. PMID: 31786414    Free PMC article.
Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study.
Jiayi Wu, Shuning Ding, +16 authors, Li Zhu.
Cancer Res Treat, 2020 Feb 06; 52(3). PMID: 32019280    Free PMC article.
Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30.
Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen.
Oncol Lett, 2020 Jul 30; 20(2). PMID: 32724396    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.
Nina Ditsch, Michael Untch, +42 authors, Achim Wöckel.
Breast Care (Basel), 2019 Sep 29; 14(4). PMID: 31558897    Free PMC article.
Review.
Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base.
Abiola Ibraheem, Olufunmilayo I Olopade, Dezheng Huo.
Cancer, 2020 Jun 11; 126(17). PMID: 32521056    Free PMC article.
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database.
In Sil Choi, Jiwoong Jung, +5 authors, Ki-Tae Hwang.
Cancers (Basel), 2020 Jul 12; 12(7). PMID: 32650374    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
Review.
Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer.
Li-Tong Yao, Mo-Zhi Wang, +5 authors, Ying-Ying Xu.
World J Clin Cases, 2019 Aug 20; 7(15). PMID: 31423426    Free PMC article.
Review.
Genomic Signatures in Luminal Breast Cancer.
Julian Puppe, Tabea Seifert, +3 authors, Wolfram Malter.
Breast Care (Basel), 2020 Sep 29; 15(4). PMID: 32982645    Free PMC article.
Review.
Do we still need breast cancer screening in the era of targeted therapies and precision medicine?
Rubina Manuela Trimboli, Paolo Giorgi Rossi, +4 authors, Francesco Sardanelli.
Insights Imaging, 2020 Sep 26; 11(1). PMID: 32975658    Free PMC article.
Review.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Review.
First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Johannes Ettl, Sophie-Isabelle Anders, +5 authors, Marion Kiechle.
Arch Gynecol Obstet, 2020 Sep 10; 302(6). PMID: 32902674    Free PMC article.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Ulrike Nitz, Oleg Gluz, +18 authors, Nadia Harbeck.
Breast Cancer Res Treat, 2017 Jul 01; 165(3). PMID: 28664507    Free PMC article.
[Ki67: biological intertumor variance versus variance of assay].
H Kreipe.
Pathologe, 2018 Oct 18; 39(Suppl 2). PMID: 30327857
Review.
SEOM clinical guidelines in early stage breast cancer (2018).
F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868    Free PMC article.
[Update of the German S3 breast cancer guideline : What is new for pathologists?]
A Lebeau, C Denkert, +2 authors, A Wöckel.
Pathologe, 2019 Mar 09; 40(2). PMID: 30847505
Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.
Norbert Marschner, Tanja Trarbach, +7 authors, TMK-Group (Tumour Registry Breast Cancer).
Breast Cancer Res Treat, 2019 Mar 15; 175(3). PMID: 30868393    Free PMC article.
Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
Peter McAnena, Kahraman Tanriverdi, +4 authors, Michael J Kerin.
BMC Cancer, 2019 May 12; 19(1). PMID: 31077182    Free PMC article.
Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019).
Michael Untch, Christoph Thomssen, +21 authors, Nadia Harbeck.
Geburtshilfe Frauenheilkd, 2019 Jun 21; 79(6). PMID: 31217628    Free PMC article.
An Improved, Assay Platform Agnostic, Absolute Single Sample Breast Cancer Subtype Classifier.
Mi-Kyoung Seo, Soonmyung Paik, Sangwoo Kim.
Cancers (Basel), 2020 Dec 02; 12(12). PMID: 33255759    Free PMC article.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Stephen R D Johnston, Nadia Harbeck, +27 authors, monarchE Committee Members and Investigators.
J Clin Oncol, 2020 Sep 22; 38(34). PMID: 32954927    Free PMC article.
Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.
Peng Qi, Yu Yang, +5 authors, Xiao-Yan Zhou.
Breast Cancer Res Treat, 2021 Jan 14;. PMID: 33439420    Free PMC article.
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center.
Katya Losk, Rachel A Freedman, +7 authors, Tari A King.
Breast Cancer Res Treat, 2020 Sep 18; 185(1). PMID: 32939592
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
Kent F Hoskins, Oana C Danciu, Naomi Y Ko, Gregory S Calip.
JAMA Oncol, 2021 Jan 22;. PMID: 33475714    Free PMC article.